David Taussig

5.1k citations
56 papers · 3.2k · 1 hit paper · h-index 22

Impact in

  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
  • Immunology top 5%
    • Immune Cell Function and Interaction

Papers in

  • Hematology 34
    • Acute Myeloid Leukemia Research 28
    • Hematopoietic Stem Cell Transplantation 17
  • Molecular Biology 18
    • Protein Degradation and Inhibitors 4
    • Histone Deacetylase Inhibitors Research 4
Co-authors
Dominique Bonnet (14 shared papers)John G. Gribben (25 shared papers)T. Andrew Lister (8 shared papers)Daniel J. Pearce (3 shared papers)Farideh Miraki‐Moud (12 shared papers)A. Z. S. Rohatiner (4 shared papers)Fernando Anjos‐Afonso (7 shared papers)Jamie Cavenagh (10 shared papers)
Journals
Blood (18 papers)British Journal of Haematology (7 papers)Leukemia (2 papers)Blood Advances (2 papers)Journal of Clinical Oncology (2 papers)
Partner nations
United KingdomUnited StatesFrance

In The Last Decade

David Taussig

51 papers receiving 3.1k citations

Hit Papers

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study 2016 · 336 citations
3360+3+6Years since publication100200300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2016 The Lancet Haematology

Peers

David Taussig
Comparison fields: 5 of 96
  • Hematology 1.7k
  • Immunology 769
  • Oncology 951
  • Genetics 358
  • Cancer Research 472
Replace Claudia Voena with:
Claudia Voena Italy
Arjan Buijs Netherlands
Amy Rappaport United States
Kalindi Parmar United States
Fabiana Perna United States
Lisa A. Moreau United States
Mary L. Bath Australia
Armando G. Poeppl Canada
Sami N. Malek United States
Mathijs Baens Belgium
David Taussig relative to Claudia Voena Italy Claudia Voena's profile →
Citations per field
00.5×2×2.6×
Claudia Voena · 1×
Citations per year

Countries citing papers authored by David Taussig

Since Specialization
Citations

This map shows the geographic impact of David Taussig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Taussig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Taussig more than expected).

Fields of papers citing papers by David Taussig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Taussig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Taussig. The network helps show where David Taussig may publish in the future.

Co-authors

The 25 scholars most cited alongside David Taussig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Taussig Line = papers co-authored together David Taussig links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
The Lancet Haematology ·Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez‐Roca, Karen Yee, David Taussig, Keyvan Rezaï, Christophe Roumier, Patrice Herait, Carmen Kahatt, Bruno Quesnel, Mauricette Michallet, Christian Récher, François Lokiec, Claude Preudhomme, Hervé Dombret
Hit paper breakdown →		2016336
2
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
Blood ·David Taussig
2005284
3
Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
Blood ·David Taussig, Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Daniel J. Pearce, Kirsty Allen, Christopher M. Ridler, Debra M. Lillington, Heather Oakervee, Jamie Cavenagh, Samir Agrawal, T. Andrew Lister, John G. Gribben, Dominique Bonnet
2008278
4
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction
Blood ·David Taussig, Jacques Vargaftig, Farideh Miraki‐Moud, Emmanuel Griessinger, Kirsty Sharrock, Tina Luke, Debra M. Lillington, Heather Oakervee, Jamie Cavenagh, Samir Agrawal, Tim Lister, John G. Gribben, Dominique Bonnet
2010262
5
Characterization of Cells with a High Aldehyde Dehydrogenase Activity from Cord Blood and Acute Myeloid Leukemia Samples
Stem Cells ·Daniel J. Pearce, David Taussig, Catherine Simpson, Kirsty Allen, A. Z. S. Rohatiner, T. Andrew Lister, Dominique Bonnet
2005235
6
Improving CRISPR–Cas specificity with chemical modifications in single-guide RNAs
Nucleic Acids Research ·Daniel E. Ryan, David Taussig, Israel Steinfeld, Smruti M. Phadnis, Benjamin D. Lunstad, Madhurima Singh, Xuan Vuong, Kenji D. Okochi, Ryan McCaffrey, Magdalena Olesiak, Subhadeep Roy, Chong Wing Yung, Bo Curry, Jeffrey R. Sampson, Laurakay Bruhn, Douglas J. Dellinger
2017214
7
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
Blood ·Rifca Le Dieu, David Taussig, Alan G. Ramsay, Richard Mitter, Faridah Miraki-Moud, Rewas Fatah, Abigail M. Lee, T. Andrew Lister, John G. Gribben
2009191
8
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
Blood ·Daniel J. Pearce, David Taussig, Kazem Zibara, Lan‐Lan Smith, Christopher M. Ridler, Claude Preudhomme, Bryan D. Young, A. Z. S. Rohatiner, T. Andrew Lister, Dominique Bonnet
2005177
9
HIF-2α Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress
Cell stem cell ·Kevin Rouault‐Pierre, Lourdes López-Onieva, Katie Foster, Fernando Anjos‐Afonso, Isabelle Lamrissi‐Garcia, Martin Serrano-Sanchez, Richard Mitter, Zoran Ivanović, Hubert de Verneuil, John G. Gribben, David Taussig, Hamid Rezvani, Frédéric Mazurier, Dominique Bonnet
2013143
10
Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation
Proceedings of the National Academy of Sciences ·Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Katharine Hodby, Emmanuel Griessinger, Guglielmo Rosignoli, Debra M. Lillington, Li Jia, Jeff Davies, Jamie Cavenagh, Matthew L. Smith, Heather Oakervee, Samir Agrawal, John G. Gribben, Dominique Bonnet, David Taussig
2013108
11
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo
Blood ·Farideh Miraki‐Moud, Essam Ghazaly, Linda Ariza‐McNaughton, Katharine Hodby, Andrew Clear, Fernando Anjos‐Afonso, Konstantinos Liapis, Marianne Grantham, Fareeda Sohrabi, Jamie Cavenagh, John S. Bomalaski, John G. Gribben, Peter W. Szlosarek, Dominique Bonnet, David Taussig
2015103
12
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti‐CD20): a retrospective cohort analysis
British Journal of Haematology ·James M. Foran, A. J. Norton, Ivana N. M. Micallef, David Taussig, John Amess, A. Z. S. Rohatiner, T. Andrew Lister
200188
13
A Niche-Like Culture System Allowing the Maintenance of Primary Human Acute Myeloid Leukemia-Initiating Cells: A New Tool to Decipher Their Chemoresistance and Self-Renewal Mechanisms
Stem Cells Translational Medicine ·Emmanuel Griessinger, Fernando Anjos‐Afonso, Irene Pizzitola, Kevin Rouault‐Pierre, Jacques Vargaftig, David Taussig, John G. Gribben, François Lassailly, Dominique Bonnet
201481
14
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
Blood Advances ·Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa Hasle, Andrzej Hellmann, David Taussig, Mar Tormo, Maria Teresa Voso, James D. Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman
202164
15
CD34− Cells at the Apex of the Human Hematopoietic Stem Cell Hierarchy Have Distinctive Cellular and Molecular Signatures
Cell stem cell ·Fernando Anjos‐Afonso, Erin Currie, Héctor G. Pálmer, Katie Foster, David Taussig, Dominique Bonnet
201364
16
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia
British Journal of Haematology ·Ing Soo Tiong, Richard Dillon, Adam Ivey, Tse‐Chieh Teh, Phillip Nguyen, Nicholas J. Cummings, David Taussig, Annie‐Louise Latif, Nicola Potter, Manohursingh Runglall, Nigel H. Russell, Kavita Raj, Anthony P. Schwarer, Chun Yew Fong, Andrew Grigg, Andrew H. Wei
202064
17
Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
Blood ·Amer M. Zeidan, James D. Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac W. Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, C.L. Beach, Lewis R. Silverman
201960
18
Single cell analysis of clonal architecture in acute myeloid leukaemia
Leukemia ·Nicola Potter, Farideh Miraki‐Moud, Luca Ermini, Ian Titley, Gowri Vijayaraghavan, Elli Papaemmanuil, Peter J. Campbell, John G. Gribben, David Taussig, Mel Greaves
201856
19
Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia
Journal of Clinical Investigation ·Alexander Waclawiczek, Ashley Hamilton, Kevin Rouault‐Pierre, Ander Abarrategi, Manuel Garcia‐Albornoz, Farideh Miraki‐Moud, Nourdine Bah, John G. Gribben, Jude Fitzgibbon, David Taussig, Dominique Bonnet
202049
20
Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting
Journal of Clinical Oncology ·David Taussig, Andrew Davies, Jamie Cavenagh, Heather Oakervee, Denise Syndercombe‐Court, S. Kelsey, J. Amess, A. Z. S. Rohatiner, T. Andrew Lister, Michael J. Barnett
200348

About David Taussig

David Taussig is a scholar working on Hematology, Molecular Biology, Immunology, Oncology and Cancer Research, having authored 56 papers that have together received 3.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (28 papers), Hematopoietic Stem Cell Transplantation (17 papers), Immune Cell Function and Interaction (10 papers), CAR-T cell therapy research (8 papers), T-cell and B-cell Immunology (5 papers), Protein Degradation and Inhibitors (4 papers), Virus-based gene therapy research (4 papers) and Histone Deacetylase Inhibitors Research (4 papers). The work is most often cited by research in Hematology (1.7k citations), Immunology (769 citations), Oncology (951 citations), Genetics (358 citations) and Cancer Research (472 citations). David Taussig has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Dominique Bonnet, John G. Gribben, T. Andrew Lister, Daniel J. Pearce, Farideh Miraki‐Moud, A. Z. S. Rohatiner, Fernando Anjos‐Afonso, Jamie Cavenagh, Heather Oakervee and Kirsty Allen. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia, Blood Advances and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia VoenaBreakdown of academic impact, for papers by Arjan BuijsBreakdown of academic impact, for papers by Amy RappaportBreakdown of academic impact, for papers by Kalindi ParmarBreakdown of academic impact, for papers by Fabiana PernaBreakdown of academic impact, for papers by Lisa A. MoreauBreakdown of academic impact, for papers by Mary L. BathBreakdown of academic impact, for papers by Armando G. PoepplBreakdown of academic impact, for papers by Sami N. MalekBreakdown of academic impact, for papers by Mathijs Baens